Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Jul 1, 2024
auto_awesome
Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.
Combinations of BTK and BCL2 inhibitors show high efficacy in CLL, particularly in high-risk patients with genetic aberrations.
BTK degraders exhibit promising response rates in heavily pre-treated CLL patients, suggesting a new avenue for treatment.
Deep dives
Combinations of BTK and BCL2 Inhibitors in CLL
Discussions on the efficacy of combinations of BTK and BCL2 inhibitors in chronic lymphocytic leukemia (CLL) highlighted data from the Sequoia trial, showing high efficacy in a high-risk population with 17p deletion or TP53 aberrations. The combination of Serontoclax and Xanabarutinib in relapsed CLL patients demonstrated excellent response rates and promising tolerability, moving into a randomized clinical trial for further validation.
Potential of BTK Degraders in Relapse Refractory Patients
Insights into BTK degraders, a new class of drugs binding to BTK for degradation, showed promising response rates in heavily pre-treated patients with CLL. The data from early studies indicated approximately 70% response rates in patients post-covalent BTK treatment, with ongoing assessment needed for long-term efficacy and understanding of subgroups.
Advancements in Richter Transformation with Epcoritamab
Updates on Richter transformation discussed the promising results of Epcoritamab in achieving around a 60% overall response rate in a refractory patient population. The treatment showed a manageable safety profile with notable complete remission rates. Future studies exploring Epcoritamab in combination with other treatments offer potential for long-term disease control in Richter transformation cases.
In today’s VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the treatment of RT.